Our approach involves tethering of NTA
functionality to Baylis-Hillman group through the ester group using a flexible
linker. In that case formation of Ni2+ ternary complex between
hexahistidine fragment and NTA would bring the reactive double bond of
Baylis-Hillman ester group into the vicinity of one of imidazole rings that do
not form the coordination bond with Ni2+ cation. The resultant
addition-elimination process would form a C-N covalent bond while breaking
linkage with NTA function leaving the ArCH=CH(CO2Me)CH2-
moiety attached to hexahistidine residue.
The reaction of alkylation can be used for introduction of a "sticky end" group such as alkynyl which can be a versatile substrate for a subsequent bioorthogonal reaction to introduce variety of functionalities. To prove this approach a sample of recombinant Protein A possessing a hexahistidine tag was alkylated with alkynyl carrying ester 7b to perform two stage derivatization with a fluorescent functionality. On the first stage Protein A (16 M) was treated with 2 eq. of ester 7b, 6 eq. of N-methylimidazole, and 2 eq. of either Cu2+ or Zn2+ cations to produce alkynyl functionalized protein 13. To determine the rate of possible intermolecular alkylation of Protein A of the hexahistidine sequence, or of any other reaction site, a control experiment in the absence of these metal cations was also performed.
The hexahistidine group can be alkylated in aqueous solutions at micromolar concentrations of reagents assembled from Baylis-Hillman esters tethered to nitrolotriacetate function through a flexible linker. The reaction is templated by formation of quaternary complex composed from these reactants, a monodentate ligand such as N-methylimidazole, and a metal cation such as Ni2+, Cu2+, or Zn2+. While currently achieved alkylation time are currently higher than in the existing bioconjugation methods, this reaction can be a promising way for specific derivatization of recombinant proteins possessing a hexahistidine tail through introduction of an alkynyl function that can be used for subsequent bioorthogonal cycloaddition reactions. Studies of this versatile approach are currently being extended to development of new alkylating agents to perform derivatizations of recombinant proteins with quantitative yield using stoichiometric amounts of reagents under low micromolar concentrations in vitro and in vivo.